Form 4: Coherus BioSciences Director Acquires Stock Options
SEC Form 4 Filing
Michael Lee Ryan, a director at Coherus BioSciences, acquired stock options for 112,000 shares on June 3, 2024.
Summary
- On June 3, 2024, Michael Lee Ryan, a director of Coherus BioSciences, Inc., was granted stock options.
- The options give him the right to buy 112,000 shares of Coherus BioSciences common stock at an exercise price of $1.76 per share.
- The options vest 100% on June 3, 2025, contingent upon Ryan's continued service with the company.
- The options expire on June 3, 2034.
Sentiment
Score: 5
Explanation: Neutral sentiment. This is a routine disclosure of stock option grants to a director.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. It's common for directors and officers to receive stock options as part of their compensation.
Stakeholder Impact
- The granting of stock options to a director could potentially align the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/03/2024 | Date of the stock option grant. |
| 06/03/2025 | Date when the stock options vest 100%. |
| 06/03/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.